Achondroplasia Treatment: FDA Approves Yuviwel as First Once-Weekly Therapy for Children

On February 27, 2026, Yuviwel (navepegritide) became the first once-weekly achondroplasia treatment cleared by the FDA for children ages 2 and older. Pediatricians now have an alternative to daily vosoritide, with phase 2b data showing a 1.49 cm/year growth velocity advantage over placebo.

February 28, 2026 · 4 min read

The Story at a Glance:

Yuviwel (navepegritide) becomes the first once-weekly achondroplasia treatment FDA-approved for children ages 2 and older with open epiphyses.
Accelerated approval rests on annualized growth velocity (AGV), a surrogate endpoint, with continued approval contingent on confirmatory data.
In the phase 2b APPROACH trial, AGV reached 5.89 cm/year on navepegritide versus 4.41 cm/year on placebo.
Vosoritide (Voxzogo, daily SC) remains the only other approved disease-specific option; no head-to-head trial exists.

What Happened

The FDA approved a second achondroplasia treatment for pediatric patients on February 27, 2026, granting accelerated approval to Ascendis Pharma’s Yuviwel (navepegritide), a once-weekly C-type natriuretic peptide (CNP) prodrug. The indication covers children ages 2 years and older with achondroplasia and open epiphyses.

Navepegritide is engineered to release active CNP gradually over the dosing interval, sustaining systemic exposure through receptor-mediated antagonism of the FGFR3-MAPK pathway that drives short stature. Yuviwel is supplied as a lyophilized powder for subcutaneous injection in 1.3 mg, 2.8 mg, and 5.5 mg single-dose vials, with weight-based dosing of 100 μg/kg once weekly.

The FDA also issued a Rare Pediatric Disease Priority Review Voucher to Ascendis Pharma at approval. Continued approval depends on confirmatory clinical benefit data from ongoing trials. Commercial availability in the United States is expected in early Q2 2026.

Why This Achondroplasia Treatment Is Different

This is the second precision pharmacotherapy for achondroplasia, after vosoritide (Voxzogo) was approved in 2021. Both drugs work through CNP signaling, but the dosing schedules differ substantially: vosoritide is a daily subcutaneous injection, while navepegritide is given once weekly.

The placebo-adjusted growth-velocity gains are broadly similar across separate trials. Vosoritide’s pivotal phase 3 study showed approximately 1.6 cm/year over placebo, and navepegritide’s APPROACH trial showed 1.49 cm/year (95% CI 1.05–1.93). No head-to-head study has been performed, and cross-trial comparisons should be interpreted cautiously given different designs and populations.

Two practical differences for prescribers: navepegritide’s label does not require pre-dose hydration or food, unlike vosoritide, and navepegritide is not recommended for children with moderate or severe renal impairment (eGFR <60 mL/min/1.73 m²). Achondroplasia affects roughly 1 in 20,000–30,000 live births and accounts for about 90% of disproportionate short stature.

Key Numbers from the Achondroplasia Treatment Trial

The pivotal phase 2b APPROACH trial (NCT05598320) was a randomized, double-blind, placebo-controlled study of 84 treatment-naïve children aged 2 to 11 years with genetically confirmed achondroplasia, conducted across seven countries. Participants were randomized 2:1 to navepegritide 100 μg/kg weekly (n=57) or placebo (n=27) for 52 weeks, followed by an open-label extension. Detailed results were published in JAMA Pediatrics in November 2025.

Primary endpoint — AGV at week 52: 5.89 cm/year on navepegritide vs 4.41 cm/year on placebo; least-squares mean difference 1.49 cm/year (95% CI, 1.05–1.93; P<0.001).
Children ages 2 to <5 years (n=21): least-squares mean AGV 6.07 cm/year on navepegritide.
Achondroplasia-specific height z-score: least-squares mean treatment difference of 0.28 favoring navepegritide.
Skeletal alignment: improvements in tibial-femoral angle, mechanical axis deviation, and fibula-to-tibia length ratio.

Common adverse reactions (≥5%) on navepegritide were vomiting, transient injection-site reactions, extremity pain, and nausea; hypertrichosis occurred in 3%. Injection-site reactions affected 19.3% of navepegritide recipients versus 14.8% on placebo and were all transient and mild. No treatment-related serious adverse events, including symptomatic hypotension or fractures, were reported.

What Experts Are Saying

Carlos A. Bacino, MD, FACMG, Professor of Molecular and Human Genetics at Baylor College of Medicine and Texas Children’s Hospital — and an investigator on APPROACH — has framed the approval as a meaningful expansion of options for families.

“A major step forward in the treatment of children with achondroplasia.” — Carlos A. Bacino, MD, FACMG, Baylor College of Medicine; ApproaCH trial investigator

Independent academic commentary in the Pediatric Endocrine Society’s drug review has been more cautious. The PES summary highlights that long-term outcomes — adult height, complication rates, sleep-disordered breathing, and quality of life — remain unproven, and that the absence of head-to-head data with vosoritide leaves choice between agents largely a question of dosing convenience and tolerability profile rather than demonstrated superiority.

What’s Next for Achondroplasia Treatment

Ascendis expects U.S. commercial supply to begin in early Q2 2026 through a dedicated patient access program. Confirmatory trials and longer open-label extension data will be needed to determine whether weekly CNP exposure translates into adult height gains, fewer foramen magnum or spinal complications, or improved functional outcomes.

A third investigational agent, the oral FGFR-selective tyrosine kinase inhibitor infigratinib, is also moving through pediatric trials and could broaden the class further. For now, pediatricians should expect referrals for treatment evaluation to rise as families weigh weekly versus daily injectable options. Insurance coverage and access programs through Ascendis Signature Access will shape uptake.

Bottom Line

Refer children with achondroplasia for treatment evaluation early — both Yuviwel and vosoritide require open epiphyses, and the benefit window narrows as bone age advances.
Counsel families that navepegritide is once-weekly subcutaneous and that growth-velocity gains are broadly similar to vosoritide on cross-trial comparison, with no head-to-head data.
Screen for moderate-to-severe renal impairment (eGFR <60 mL/min/1.73 m²) before initiation — Yuviwel is not recommended in that group.
Build a monitoring plan with periodic growth assessment, weight-based dose adjustments, and symptom-based watch for dizziness or fatigue from transient hypotension; pre-dose hydration is not required.
Plan to discontinue therapy once bone age confirms epiphyseal closure, and continue tracking achondroplasia-related complications including sleep apnea, ear infections, spinal stenosis, and hydrocephalus.

Sources

Ascendis Pharma A/S. FDA Approves Once-Weekly YUVIWEL (navepegritide) for Children with Achondroplasia Aged 2 Years and Older. February 27, 2026. Ascendis Pharma Press Release — Yuviwel Approval
Savarirayan R, McDonnell C, Bacino CA, et al. Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical Trial. JAMA Pediatrics, November 17, 2025. JAMA Pediatrics — APPROACH Trial Full Text
Ryabets-Lienhard A. Navepegritide (Yuviwel) for Children with Achondroplasia: New Drugs and Therapeutics. Pediatric Endocrine Society, March 2026. Pediatric Endocrine Society — Navepegritide Drug Review
Brooks J. FDA Grants Accelerated Approval to Navepegritide for Achondroplasia in Children Aged 2 Years and Older. HCPLive, March 2026. HCPLive — Navepegritide Approval Coverage
Cheraskin R. FDA Approves Navepegritide for Children With Achondroplasia. Pharmacy Times, March 2026. Pharmacy Times — Navepegritide Approval
Contemporary Pediatrics editors. FDA Issues Historic Approval for Navepegritide in Achondroplasia. Contemporary Pediatrics, February 2026. Contemporary Pediatrics — Yuviwel Approval
Patel S, Brouillette J, Stagi S. Achondroplasia treatments in children aged 5 and older. Molecular and Cellular Pediatrics, October 2025. Molecular and Cellular Pediatrics — Cross-Therapy Review